181 related articles for article (PubMed ID: 15998926)
41. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
Bays HE; Davidson M; Jones MR; Abby SL
Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
[TBL] [Abstract][Full Text] [Related]
42. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
43. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
[TBL] [Abstract][Full Text] [Related]
44. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
[TBL] [Abstract][Full Text] [Related]
45. A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
Tárraga-López PJ; Celada-Rodríguez A; Cerdán-Oliver M; Solera-Albero J; Ocaña-López JM; López-Cara MA; De Miguel-Clave J
Pharmacoeconomics; 2005; 23(3):275-87. PubMed ID: 15836008
[TBL] [Abstract][Full Text] [Related]
46. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
47. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
[TBL] [Abstract][Full Text] [Related]
48. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
[TBL] [Abstract][Full Text] [Related]
49. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme a reductase inhibitors on attainment of LDL-C goals.
Bradford WD; Kleit AN; Nietert PJ; Ornstein S
Clin Ther; 2006 Dec; 28(12):2105-18; discussion 2104. PubMed ID: 17296467
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
51. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016.
Romanelli RJ; Ito MK; Karalis DG; Huang HC; Iorga ŞR; Kam IW; Thompson S; Azar KMJ
J Clin Lipidol; 2020; 14(3):305-314. PubMed ID: 32362513
[TBL] [Abstract][Full Text] [Related]
52. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
Plakogiannis R; Cohen H
Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
[TBL] [Abstract][Full Text] [Related]
53. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
54. Adherence to statins and LDL-cholesterol goal attainment.
Chi MD; Vansomphone SS; Liu IL; Cheetham C; Green KR; Scott RD; Reynolds K
Am J Manag Care; 2014 Apr; 20(4):e105-12. PubMed ID: 24884955
[TBL] [Abstract][Full Text] [Related]
55. Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.
Hong MK; Lee CW; Kim YH; Park DW; Lee SW; Park CB; Jang JS; Han KH; Cheong SS; Kim JJ; Park SW; Park SJ
Am J Cardiol; 2006 Oct; 98(7):866-70. PubMed ID: 16996864
[TBL] [Abstract][Full Text] [Related]
56. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
57. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates.
Baessler A; Fischer M; Huf V; Mell S; Hengstenberg C; Mayer B; Holmer S; Riegger G; Schunkert H
Int J Cardiol; 2005 May; 101(2):293-8. PubMed ID: 15882678
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.
Benner JS; Smith TW; Klingman D; Tierce JC; Mullins CD; Pethick N; O'Donnell JC
Value Health; 2005; 8(6):618-28. PubMed ID: 16283862
[TBL] [Abstract][Full Text] [Related]
59. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.
Obońska K; Kasprzak M; Sikora J; Obońska E; Racki K; Goździkiewicz N; Krintus M; Kubica J
Trials; 2017 Jul; 18(1):316. PubMed ID: 28697767
[TBL] [Abstract][Full Text] [Related]
60. Statin adherence and LDL cholesterol levels. Should we assess adherence prior to statin upgrade?
Vodonos A; Ostapenko I; Toledano R; Henkin Y; Zahger D; Wolak T; Sherf M; Novack V
Eur J Intern Med; 2015 May; 26(4):268-72. PubMed ID: 25770073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
